Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAdCaP: MDM2 inhibition and abiraterone in prostate cancer
ISRCTN38949950Phase 2Completed
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Feb 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of idasanutlin, abiraterone and prednisolone in prostate cancer (PCa) (3 arms), sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: Radiological progression-free survival. Started Feb 2014; status: completed.
02
Drugs
idasanutlinabirateroneprednisolone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ISRCTN38949950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN38949950.